European urology, vol.77, no.4, pp.508-547, 2020 (Journal Indexed in SCI Expanded)
Article / Article
Title of Journal :
Advanced prostate cancer, High-risk localised prostate cancer, Hormone-sensitive prostate cancer, Castration-resistant prostate cancer, Oligometastatic prostate cancer, Progression-free survival, Overall survival, Prostate cancer treatment, Imaging, Genetics, Tumour genomic profiling, ANDROGEN-DEPRIVATION THERAPY, SALVAGE RADIATION-THERAPY, LYMPH-NODE DISSECTION, QUALITY-OF-LIFE, HOT FLASHES, RADICAL PROSTATECTOMY, CLINICAL-TRIALS, FREE SURVIVAL, PHASE-II, TESTOSTERONE MEASUREMENTS
Background: Innovations in treatments, imaging, and molecular characterisation in advanced prostate cancer have improved outcomes, but there are still many aspects of management that lack high-level evidence to inform clinical practice. The Advanced Prostate Cancer Consensus Conference (APCCC) 2019 addressed some of these topics to supplement guidelines that are based on level 1 evidence.